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Open access under CC BY license.The emergence of artemisinin resistance could adversely
impact the current strategy for malaria treatment; thus,
new drugs are urgently needed. A possible approach to
developing new antimalarials is to find new uses for old
drugs. Some anticancer agents such asmethotrexate and
trimetrexateareactive againstmalaria.However, theyare
commonly perceived to be toxic and thus not suitable for
malaria treatment. In this opinion article, we examine
how the toxicity of anticancer agents is just a matter of
dose or ‘only dose makes the poison’, as coined in Para-
celsus’ law. Thus, the opportunity exists to discover new
antimalarials using the anticancer pharmacopoeia.
The need for new antimalarial drugs
The malaria parasite, the cause of one of the most signifi-
cant infectious diseases, is characterised by an intrinsic
ability to select for resistance against drugs. To slow down
the pace of resistance selection, it has been recommended
that antimalarials be used in combinations of at least two
drugs with different modes of action, and the current
recommendation is to use artemesinin-based combinations
[1]. However, recent reports indicate that resistance to
artemesinin is emerging in Southeast Asia, and there
are concerns that the therapeutic life span of artemisinin
combinations might be compromised [2]. The choices for
combination therapy could be reduced and, as a result,
drug resistance would remain a limitation to sustaining
effective malaria treatment.
One approach for discovering new antimalarials is to re-
use drugs developed for the treatment of other diseases.
The literature is replete with examples of new uses for old
drugs. For example, among the few drugs that are avail-
able in the treatment of malaria, quinine is used to treat
muscle cramps [3], and chloroquine (CQ) (preferably
hydroxyl-chloroquine) is used for the management of
rheumatoid arthritis and systemic lupus erythematosus
[4]. Artemisinin is being investigated for the treatment of
schistosomiasis and cancer [5,6]. However, thus far, there
is no drug that has been re-used for acute malarial treat-
ment, in spite of the richness of the human pharmacopoeia.
Only drugs, such as the antibiotic doxycycline, azithromy-
cin and erythromycin, have been used, or are currently
being investigated, for prophylaxis against malaria [7,8].
Dapsone, a drug used to treat leprosy and dermatitisCorresponding author: Nzila, A. (anzila@kilifi.kemri-wellcome.org).
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(Lapdap1) [10]; however, this combination has been
phased out because of dapsone toxicity.
Antimalarial potential of methotrexate and
trimetrexate, in vitro
There is evidence that anticancer compounds methotrexate
(MTX) and trimetrexate (TMX) are active against both
pyrimethamine (PM)-sensitiveandPM-resistant laboratory
strains and field isolates of Plasmodium falciparum,
including those carrying the Ileu164-Leu dhfr codon
(dihydrofolate reductase, DHFR), with IC50 < 85 nM
(inhibitor concentration that kills 50% of parasitaemia)
[11], and IC90/99 values for these folate antagonist agents
fall between 150 and 350 nM; thus, if such a concentration
can be achieved in vivo with an acceptable toxicity profile,
these compounds could potentially beusedasantimalarials.
However, anticancer agents in general, andMTX in particu-
lar, are perceived to be toxic and therefore not suitable for
malaria treatment. Yet the literature is replete with
examples of new uses of anticancer agents in the treatment
of non-neoplastic diseases (Table 1).
Anticancer toxicity and Paracelsus’ law
The inhibition of pathways or enzymes in tumour cells also
affects normal human cells. Some anticancer agents are
directed against cancer-specific targets [e.g. Imatinibmesy-
late (GleevecTM) targets cancer-specific tyrosine kinases]
and thuscanbeusedatdoseswitha relativelybetter toxicity
profile than most drugs [12]. However, most anticancer
agents are used at doses that also lead to the inhibition of
growth of normal cells, in addition to blocking tumourous
cells. Most specifically affected are cells that multiply
actively, such as bone marrow cells, e.g. leukocytes, cells
of thegastrointestinalmucosaandhair follicle cells, explain-
ing why bone marrow suppression, mucositis and alopecia
(hair loss) are among the most common side effects of antic-
ancer compounds. However, according to Paracelsus’ law,
for any drug (including anticancers), there is always a dose
range at which a drug is safe.
Paracelsus’ law states ‘Sola dosis facit venenum (only
dose makes the poison)’, meaning that all substances are
poisons and there are none which are not. The right dose
differentiates a poison from a remedy; this principle is also
known as the ‘dose–response effect’ [13,14] (Figure 1). Thus,
a molecule becomes a drug if the dose required to treat aAvailable online 6 January 2010 125
Table 1. Selected oncologic drugs used in the treatment of non-neoplastic diseasesa
Drug Mechanism of action Neoplasm (oncology) Non-neoplasm Refs
Dose rangeb and indications Toxicity profilec Dose rangeb and indications Toxicity profilec
MTX 200–2000 mg per dose Grade 3 7.5–35 mg per week Grade 0–1 [19,20,22]
Folate antimetabolite,
inhibits DNA synthesis
ALL, breast cancer, head and
neck cancer, NHL, lung
cancer, osteosarcoma,
Trophoblastic neoplasm
Neurological, gastrointestinal and
dermatological symptoms.
Pulmonary, bone marrow, renal
and hepatic toxicity
Crohn’s disease, rheumatoid
arthritis, JIA, psoriasis, psoriatic
arthritis
Gastrointestinal symptoms,
transient elevation of liver
enzymes, liver dysfunction
Cyclophosphamide DNA alkylating agent,
inhibits DNA synthesis
250–1300 mg per dose Grade 3 75–250 mg per dose Grade 0–1 [51]
ALL, breast cancer, Burkitt
lymphoma, HD, NHL, MM,
ovarian cancer,
retinoblastoma
Gastrointestinal, dermatological
and catarrhal symptoms. Bone
marrow, renal, hepatic,
pulmonary toxicity. Acute
haemorrhagic cystitis, infertility
Behcet’s syndrome, idiopathic
pulmonary fibrosis, ITP, JIA, lupus
nephritis, NS, SLE, transplant
rejection prophylaxis, multiple
sclerosis, Wegener’s
granulomatosis
Fatigue, gastrointestinal,
catarrhal and dermatological
symptoms
6-Mercapto-purine Purine antagonist, inhibitor
of DNA and RNA synthesis
150–350 mg per dose Grade 3 100–150 mg per dose Grade 1–2 [52]
ALL, AML, CML Gastrointestinal and
dermatological symptoms. Bone
marrow, hepatic and renal toxicity
Crohn’s disease, ulcerative colitis Gastrointestinal symptoms,
bone marrow suppression,
elevation of liver enzymes
Thalidomided Mechanism of action is
not completely understood.
Selectively reduces
levels of TNF
200–1200 mg per dose Grade 2–3 25–100 mg per dose Grade 0–1 [53]
Kaposi’s sarcoma, MM,
malignant glioma,
myelodysplastic syndrome,
renal cell cancer
Neurological and dermatological
symptoms. Bone marrow
suppression, increased risk of
thrombosis
Behcet’s syndrome, Crohn’s
disease, SLE, DLE
Neurological symptoms
Vincristine Vinca alkaloid: inhibitor of
microtubule formation,
stopping cell division
2–3.5 mg per week Grade 3 2 mg per month Grade 0–1 [54]
ALL, HD, malignant glioma,
neuroblastoma, NHL
rhabdomyosarcoma, Wilms’
tumour
Neurological, gastrointestinal and
dermatological symptoms. Bone
marrow suppression,
neurotoxicity
ITP,TTP Neurological symptoms
DFMOe Inhibitor of ornithine
decarboxylase
>10 g per dosee Grade 4 0.4–0.8 g per day for a year Grade 0–1 [55,56]
Prostate cancer Diarrhoea, abdominal pain,
alopecia and ototoxicity
Chemoprotection against prostate
cancer, actinic keratosis
>0.4 g per day for several months Grade 0–1
As a cream Hirsutism (facial hair)
>5 g per day for 15 days Grade 1–2
Sleeping sickness
(trypanosomiasis)
Gastrointestinal symptoms
Miltefosinef Inhibitors of phospholipid
biosynthesis of cell
membrane
x x 1.5–2.5 mg per kg for 28 days
Leishmaniasis
Grade 1–2 [57]
Nausea, vomiting, diarrhoea
aAbbreviations: ALL = acute lymphocytic leukaemia, AML = acute myelogenous leukaemia, CLL = chronic lymphocytic leukaemia, CML = chronic myelogenous leukaemia, DLE = discoid lupus erythematosus, HD = Hodgkin’s disease,
ITP = idiopathic thrombocytopenic purpura, JIA = juvenile idiopathic arthritis, MM = multiple myeloma, NHL = non-Hodgkin’s lymphoma, NS = nephritic syndrome, SLE = systemic lupus erythematosus, TTP = thrombotic thrombo-
cytopenic purpura.
bAdult doses.
cGrade 0 = no adverse reaction, Grade 1 = mild adverse reactions, Grade 2 = moderate adverse reactions, Grade 3 = severe adverse reactions, Grade 4 = life-threatening toxicity.
dNot used in pregnancy because of its effect against foetal growth teratogenicity.
eDFMO (Difluoro-methyl-ornithine)was used as an experimental drug in cancer butwas abandoned because efficacy could only be achievedwith doses associatedwith serious life-threatening toxicity. However, the drugwas revived for
cancer chemoprotection, hirsutism and trypanosomiasis treatment at low dose.
fMiltefosine was initially discovered as an antineoplastic drug; however, few studies were carried out in humans to treat cancer, thus detailed information on its toxicity and dose ranges as an antineoplastic is not available.
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Figure 1. Dose–response effect of drugs in humans, as per Paracelsus’ law, using methotrexate (MTX) as an example. For any drug, there is a dose range (concentration)
that is without any effect, one with a pharmacological effect but with minimal toxicity (or acceptable safety profile) and another with pharmacological and toxic effects. Most
drugs used in the treatment of human diseases fall within the middle group. In the case of MTX, experience in multiple sclerosis indicates that a dose of 7.5 mg per week for
up to 2 years is not associated with toxicity [21]. The use of 7–30 mg per week LD–MTX in the treatment of rheumatoid and juvenile arthritis and psoriasis is associated with
an acceptable toxicity profile [19]. Higher doses (<100 mg) are associated with toxicity, as shown in the treatment of cancer [18].
Openion Trends in Parasitology Vol.26 No.3complication is pharmacologically active with minimal
toxicity.
The example of CQ is noteworthy. CQ is used at 10 mg
kg–1 as a starting dose on days 1 and 2, and at 5 mg kg–1 on
day 3 [15]. At this dose regimen, CQ has an acceptable
safety profile. However, a dose of 20 mg kg–1 is considered
toxic [15], and fatal cases have been reported from doses as
low as 30 mg kg–1, only three times higher than the thera-
peutic dose [16,17]. This indicates that a slight dose
increase shifts the effect of CQ from the second range
(acceptable safety profile with a pharmacological effect)
to the third range (life-threatening toxicity) (Figure 1).
Thus, CQ has a very low safety margin, and yet it has
been used widely (at the correct dose) and is considered to
be one of the safest antimalarial agents available.
Different uses of MTX in humans
MTX is another interesting example. MTX is used at high
dose, up to 5000–12,000 mg per square meter (m2) per
week (130–300 mg kg–1) for several weeks for the treat-
ment of cancer, and this dose can yield serum concen-
trations of >1000 mM, i.e. within the range of
concentrations that is associated with MTX life-threaten-
ing toxicity [18]. By contrast, a 1000-fold lower dose ofMTX
(LD–MTX) [0.1–0.4 mg kg–1 (7.5–30 mg per adult)] is used
once weekly in the treatment of rheumatoid arthritis (RA),
juvenile idiopathic arthritis in children (including infants
<1 year old) and psoriasis [19,20].
The most common side effect of LD–MTX is mucositis
(oral ulcers) and gastrointestinal (GI) tract disturbances,
particularly nausea. Commonly, these adverse effects are
observed after several weeks and somewhat higher doses of
MTX (more than 15 mg in adults) [19]. Indeed, in the treat-
ment of adult RA, MTX starts at a dose of 7.5 mg once
weekly. After a few weeks, this dose is increased by2.5 mg per week (the timing of the increase could vary,
depending on how the patient is responding to the treat-
ment), to reach a final dose of 25–35 mg per week. The
toxicity of MTX is observed when it is used at doses
>7.5 mg per week and several weeks after the first drug
administration. The toxicity of MTX is a result of inhibition
of the DHFR enzyme in normal cells. To prevent toxicity, a
folate derivative is administered several hours after the
dose of MTX. The addition of folate derivatives increases
either dihydrofolate or tetrahydrofolate (DHFR substrate
and product, respectively). In either case, the action ofMTX
against DHFR will be minimal because of the high folate
content, leading to normal synthesis of pyrimidine and the
restoration of cell growth. In juvenile arthritis, MTX is used
at a higher dose, and there is still debate over the benefit of
the addition of a folate derivative because mucositis and GI
tract disturbances are rare: this drug is better tolerated by
children than by adults [19], probably as a result of high cell
multiplication processes in children. Overall, it is clear that
the toxicity of LD–MTX result from chronic use of doses
>7.5 mg per week, as has been clearly demonstrated with
the use of MTX in the treatment of multiple sclerosis [21].
MTX is also being evaluated in the treatment of various
disease conditions including inflammatory bowel disease
[22], urticaria [23], ankylosing spondylitis [24], idiopathic
hypertrophic cranial pachymeningitis [25], chronic chole-
static disorder [26], Wegener’s granulomatosis [27],
primary biliary cirrhosis [28], systemic lupus erythemato-
sus [29] and inflammatory eye disease [30], haemophago-
cytic lymphohistiocytosis (HLH), a disease that affects
younger children, including infants (<12 months of age)
[31].
Worldwide, it is estimated that 0.5–1 million adults and
50,000–100,000 children receive LD–MTX weekly for
the treatment of RA and juvenile idiopathic arthritis,127
Openion Trends in Parasitology Vol.26 No.3respectively. The drug is now being used in the African
population, and its safety profile is similar to that reported
in the Western world [32].
Proof of concept of MTX as an antimalarial in humans
The antimalarial potential ofMTXhas been established for
almost 40 years. Two relatively small clinical trials, invol-
ving seven patients, have demonstrated that doses as low
as 2.5 mg per day for 3–5 days were effectively treating
malaria infection in humans (Plasmodium falciparum and/
or Plasmodium vivax) [33,34]. However, MTX has not come
into widespread use because of concerns over toxicity
[35,36]. At the time of the clinical trials (in the 1970 s),
no information was available on the safety of LD–MTX.
Indeed, LD–MTX started to be used for the treatment of
arthritis from the 1980 s; before then, MTX was used only
at high doses, associated with toxicity in cancer treatment.
We now have 30 years experience on the safety of LD–MTX
in adults and in children, and thus this drug could now be
re-evaluated as a potential antimalarial. Unlike its use in
immune diseases, MTX would not be used on a chronic
basis against malaria; it would be used for 3–5 days only
and thus the risk of toxicity would be even lower.
The in vivo efficacy of LD–MTX is also supported by
pharmacokinetics. Indeed, a daily dose of 5 mg in adults
(0.035–0.1 mg kg–1) could yield serumMTX concentrations
between 250 and 500 nM [37,38], concentrations which
exceed the IC90/99 concentrations required to kill the para-
site in vitro [11]. Taken together, the information warrants
further investigation of this drug as an antimalarial.
Potential of trimetrexate (TMX) as an antimalarial
TMX is used primarily for the treatment of solid tumours
[39]. Evidence is also available that TMX has good activity
againstP. falciparum, and the addition of the folate deriva-
tive 5-methyl tetrahydrofolate (5-Me-THF) does not reduce
TMX activity [40]. Thus, this form of folate could be used as
an adjuvant, in combination with TMX, to increase its
safety margin. 5-Me-THF would protect the host against
drug toxicity and it would not negate the antimalarial
activity of TMX. The same rationale has been used in
the combination TMX + folinic acid (FNA) for the treat-
ment of Pneumocystis jiroveci infection (an opportunistic
infection commonly found in association with HIV infec-
tion). TMX is active against P. jiroveci and this microor-
ganism does not salvage folate derivatives because of lack
of folate receptors and transporters; thus, the addition of
folate derivatives does not negate TMX activity. As a
result, the combination of TMX + FNA is as active as
TMX alone [41]. In cancer, a TMX dose of 100 mg per
day is used for several weeks and this is associated with
toxicity. In P. jiroveci infection, the same dose is used
(100 mg per day for 28 days) but the addition of 200 mg
of FNA completely reverses the toxicity of the drug,making
the combination TMX + FNA well tolerated. As a result,
TMX has become useful against P. jiroveci infection [42].
For the treatment of malaria, a much lower dose of TMX
would be required. Indeed, 100 mg of TMX yields plasma
concentrations of 5000 nM [43] and this is 100 times
higher than the IC50 value (i.e. <50 nM) of TMX against P.
falciparum. Thus, it is reasonable to propose that doses128<10–20 mg of TMX would be effective to treat malaria.
Such a low dose could be safe and the addition of 5-CH3-
THF could even improve the therapeutic index of the drug.
Although the potential exists for TMX to become an anti-
malarial, more work is needed to establish whether this
concept could be translated in vivo.
Other anticancer drugs in the treatment of malaria and
other non-neoplastic diseases
We have also shown that the folate antagonist pemetrexate
is active against P. falciparum in vitro, with activity in the
nanomolar range (IC50 <50 nM) (A. Nzila et al. unpub-
lished). Because the anticancers MTX, aminopterin and
pemetrexate, all inhibitors of DHFR enzymes, are active
againstP. falciparum, other anticancer inhibitors of DHFR,
such as edatrexate, pralatrexate, and piritreximmight also
be active against P. falciparum. Several other anticancer
agents have also been shown to have activity against P.
falciparum malaria. For example, the inhibitors of the
microtubulin assembly tubulozole, vinblastine, docetaxel,
paclitaxel and dolastatin [44–48], the DNA crosslinking
agent cisplatin [49] and the proteasome inhibitor Bortezo-
mib [50] are effective antimalarials in vitro. If these drugs
were active in vivo at low and tolerable doses, they could
potentially become antimalarials. This is all the more
possible in view of the fact thatmany anticancer drugs have
already been used in the treatment of non-neoplastic dis-
eases at low dose (Table 1).
Concluding remarks
The burgeoning problem of antimalarial resistance high-
lights the need to have a strong pipeline of new drugs to
treat malaria. Development of new drugs takes time and
is associated with significant costs, explaining (at least
partly) the paucity of available antimalarials, particu-
larly as this is not a profitable market and thus there is
little incentive for the pharmaceutical industry to
develop new treatments. The re-use of existing drugs
is an attractive strategy to discover new antimalarials as
the development costs would be lower and the time to
licensure shorter. Moreover, in the case of anticancer
agents, the in-human toxicity profile would have already
been well documented at much higher doses than could
ever be achieved for any other product primarily devel-
oped for malaria. Many antineoplastic drugs, including
MTX, were shown to be effective against the malaria
parasite almost 40 years ago; however, their perceived
toxicity has prevented their development as antimalar-
ials. It is now known, and as stated by Paracelsus (more
than 400 years ago), that it is ‘the dose that makes a
drug’; this principle has been exploited in the use of such
drugs at lower doses in several non-neoplastic diseases.
It is surprising that the antimalarial potential of MTX
has not been fully investigated. Exploitation of the avail-
able pharmacopoeia could be a cost-effective and efficient
channel to develop much needed alternative treatments
for challenging diseases such as malaria.
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